The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Combining FLT3 and SYK inhibition for AML
Mivavotinib (TAK-659) is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly, mivavotinib also inhibits SYK, a target that is more common in the treatment of B-cell malignancies. In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the pharmacokinetics and promising preliminary results of the Phase I trial of this agent (NCT02323113) in patients with relapsed or refractory AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
